$XBI $139.35 +0.28%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Pipeline Updates
$SLGL -12.7% Sol-Gel received no notification from FDA of approval of EPSOLAY; pre-approval inspection still needs to be conducted. source
$YMAB -1% Omburtamab MAA submitted to EMA. source
$PRVB -2.6% FDA ongoing review of teplizumab BLA; review will further be mentioned at 5/27 committee meeting. source
$SRNE +4.9% Phase 2 trial cleared to proceed. source
$RVVTF -3.6% Orphan Drug Designation for Psilocybin filed with FDA. source
$CYCN -18% Presents update on CY6463 trials; MELAS trial enrolling slowly and ADv trial to begin enrolling in mid year. source
$LUMO -4.6% Phase 2 LUM-201 data presented at webinar. source
$ZGNX -0.6% Global access program launched for FINTEPLA. source
$ESPR -4.3% Publication of CLEAR trial rationale and design evaluating NEXLETOL. source
$RVNC -0.8% First patient enrolled in Phase 3 trials of DaxibotulinumtoxinA. source
$PTGX -0.4% Enrollment in Phase 2 trial of rusfertide completed. source
$ALKS +0.1% Phase 2 ARTISTRY-6 trial initiated in patients with melanoma. source
$ALDX +33.7% Phase 3 INVIGORATE clinical trial achieves primary endpoint and all secondary endpoints. source
$RMTI -6.3% Triferic AVNU receives marketing approval in Canada. source
$ARAV +11.1% First patient dosed in Phase 3 AVB-500 trial. source
$VRNA -1.5% Phase 2b results published in International Journal of Chronic Obstructive Pulmonary Disease. source
$OBSV -2.9% PRIMROSE 3 bone mineral density study initiated for previous participants. source
Finance Updates
$ALDX +33.7% $125 million public offering of common stock. source
$LOGC -0.2% LogicBio announces collaboration with Daiichi Sankyo. source